Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE^®-RL)

Stanley CohenMetroplex Clinical Research Center, Dallas, USACorrespondence[email protected]
View further author information

Piotr A. KlimiukMedical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, PolandView further author information

Tillmann KrahnkeCogitars GmbH, Heidelberg, GermanyView further author information

Deepak AssudaniBoehringer Ingelheim, Ingelheim a.R., GermanyView further author information

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Gary T Ferguson, Jeremy Cole, Magnus Aurivillius, Paul Roussel, Peter Barker & Ubaldo J Martin. (2019) Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results. Journal of Asthma and Allergy 12, pages 363-373.
Read now

Mercedes Gimeno-Gracia, Carla J. Gargallo-Puyuelo & Fernando Gomollón. (2019) Bioequivalence studies with anti-TNF biosimilars. Expert Opinion on Biological Therapy 19:10, pages 1031-1043.
Read now

Articles from other publishers (4)

Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger & Eva Dokoupilová. (2022) Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy 9:3, pages 839-850.
Crossref

Enrico Fusaro, Patrick Durez, Johannes Wohlrab, Soohyun Lee, SangWook Yoon & Hubert Marotte. (2022) An update on the adalimumab biosimilar landscape following approval of the first high-concentration biosimilar. Immunotherapy 14:3, pages 235-252.
Crossref

Antonia Davidson, Darin Brimhall, Jonathan Kay, Edward Keystone, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Eun Jin Choi & Daniel E. Furst. (2021) Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. British Journal of Clinical Pharmacology 87:11, pages 4323-4333.
Crossref

Martin Schipperus, Georgia Kaiafa, Louise Taylor, Sally Wetten, Georg Kreuzbauer, Andy Boshier & Anouchka Seesaghur. (2018) Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study. Drug Safety 42:1, pages 77-83.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE^®-RL)

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)

Citations (6)

Read on this site (2)

Articles from other publishers (4)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE^®-RL)